Long-term survival outcomes from a phase II trial of perioperative capecitabine plus oxaliplatin for advanced gastric cancer with extensive lymph node metastases: OGSG 1701
Perioperative CapeOx therapy resulted in encouraging long-term survival in patients with advanced gastric cancer and extensive nodal metastasis. These findings support its potential role as a perioperative strategy for biologically high-risk gastric cancer, with an acceptable safety profile.
Authors
- Masahito Kotaka (ORCID: https://orcid.org/0000-0001-5976-613X)
- Shigeyuki Tamura (ORCID: https://orcid.org/0000-0002-1116-5586)
- Motohiro Imano (ORCID: https://orcid.org/0000-0003-2242-4245)
- Hiroki Takeshita
- Toshimasa Tsujinaka
- Yukinori Kurokawa
- Tomohira Takeoka
- Jin Matsuyama
- Masato Nakamura
- Hironaga Satake
- Atsushi Takeno
- Naotoshi Sugimoto
- Ryohei Kawabata
- Shogen Boku
- Toshio Shimokawa
- Taroh Satoh
- Yutaka Kimura
- Atsushi Yasuda
- Shunji Endo
Institutions
- Osaka Gakuin University (JP)
- Kansai Medical University (JP)
- Kawasaki Medical School (JP)
- Wakayama Medical University (JP)
- Osaka City General Hospital (JP)
- Sakai Municipal Hospital (JP)
- Osaka Rosai Hospital (JP)
- Kansai Rosai Hospital (JP)
- Kindai University Sakai Hospital (JP)
- Naga Municipal Hospital (JP)
- Izumi City General Hospital (JP)
- Matsushita Memorial Hospital (JP)
- Osaka International Cancer Institute (JP)
- Hyogo Prefectural Nishinomiya Hospital (JP)
- Osaka University Hospital (JP)
- Aizawa Hospital (JP)
- Kindai University (JP)
- The University of Osaka (JP)
Publication Details
- Journal
- Gastric Cancer
- Published
- 2026-03-13
- DOI
- https://doi.org/10.1007/s10120-026-01726-x
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00